News

India's Pharma Industry Now Has Its First Dedicated Manufacturer of GCHS-Grade Solvents — Advanta bioKEMIX and Resolkem Just Fixed a Critical Dependency

By Darshan S, Editor · 30 June, 2026 · 2 min read

Summary

• Advanta bioKEMIX + Resolkem Create India's First Dedicated GCHS-Grade Pharmaceutical Solvent Manufacturer
• Advanta bioKEMIX and Resolkem have formed a joint venture to establish India's first dedicated manufacturer of GCHS-grade solvents — DMF, DMA, NMP, DMSO — critical for pharmaceutical quality testing and analysis.

"India's pharmaceutical and life sciences industry has long depended on imported GCHS-grade solvents for quality testing and analysis. By combining Resolkem's technical expertise in high-purity solvent manufacturing with Advanta bioKEMIX's global distribution network and supply chain integration, Resolkem Private Limited is positioned to become the trusted domestic source of critical high-purity solvents for the Indian pharma sector."

Advanta bioKEMIX, the Indian subsidiary of the global bioKEMIX specialty chemicals network, has announced the formation of a strategic joint venture with Resolkem — a Goa-based manufacturer of high-purity Gas Chromatography-Headspace grade solvents, founded by Anand Malage, a pharmaceutical industry veteran formerly associated with Cipla. The newly incorporated entity, Resolkem Private Limited, will acquire and operate Resolkem's existing manufacturing business and equipment, combining technical expertise in high-purity solvent manufacturing with Advanta bioKEMIX's global market access, distribution network, and supply chain integration capability.

The partnership addresses a specific and structurally significant gap in India's pharmaceutical manufacturing ecosystem: the absence of a dedicated domestic manufacturer of GCHS-grade solvents — specialised high-purity chemical solvents required for pharmaceutical quality testing and analytical laboratory operations. Resolkem Private Limited is positioned as the only manufacturer of high-quality GCHS-grade solvents in India. The company currently produces a portfolio of critical GCHS solvents including Dimethyl Formamide (DMF), Dimethyl Acetamide (DMA), N-Methyl-2-pyrrolidone (NMP), and Dimethyl Sulfoxide (DMSO) — all widely used in the testing of pharmaceutical products, foods, environmental samples, and other chemical analysis where stringent quality and purity standards are critical.

Why GCHS-Grade Solvents Matter to Pharma

Gas Chromatography-Headspace analysis is a widely used analytical technique in pharmaceutical quality control, applied specifically to detect and quantify residual solvents in drug substances and drug products. ICH Q3C — the International Council for Harmonisation's guideline on residual solvents — mandates that pharmaceutical manufacturers test all drug substances and products for specified residual solvents and ensure that residual solvent levels are below established safety thresholds. The analytical method most commonly used to conduct these residual solvent tests is headspace gas chromatography — a technique that requires GCHS-grade solvents as the diluent medium for sample preparation.

The purity requirement for GCHS-grade solvents is stringent precisely because the analytical technique they support is measuring parts-per-million levels of trace chemicals. If the diluent solvent itself contains trace-level contamination, those contaminants interfere with the measurement, producing false positives or masking genuine residual solvent exceedances. High-purity GCHS-grade solvents with certified trace-level purity profiles are not optional analytical reagents — they are the prerequisite for regulatory-compliant residual solvent testing across the entire pharmaceutical manufacturing sector.

The India Supply Chain Context

India's pharmaceutical quality testing ecosystem has historically relied on imported GCHS-grade solvents from European and American specialty chemical suppliers. This import dependency creates three structural problems. Cost: imported specialty chemicals carry the combined burden of currency exchange rates, import duties, logistics costs, and supplier pricing — all of which add to the analytical cost burden for Indian pharmaceutical manufacturers, particularly smaller ones with tighter margins. Supply chain risk: import dependency concentrates supply chain risk in international logistics — precisely the category of risk that Operation Epic Fury's disruption of Middle East shipping (covered extensively in BHC Media's May-June 2026 editions) has demonstrated can materialise rapidly. Certification and traceability: customs documentation, international supplier batch certification, and the chain of custody for analytical reagents crossing international borders creates a compliance paper trail that domestic sourcing simplifies considerably.

The establishment of Resolkem Private Limited as India's first dedicated domestic GCHS-grade solvent manufacturer addresses all three structural problems simultaneously — and does so in the context of an Indian pharmaceutical regulatory environment that has dramatically increased its quality testing demands through the revised Schedule M GMP guidelines and the WHO-aligned quality standards that became mandatory for small pharmaceutical companies from January 1, 2026.

The Growth Plan

Resolkem Private Limited has outlined an ambitious growth roadmap. A significantly larger manufacturing facility is planned for establishment by Q4 2026, enabling substantial expansion of production capacity and diversification of the product portfolio beyond the current four GCHS-grade solvents. The new facility will scale up production of existing GCHS-grade products to meet rising domestic demand while enabling production of a wider range of high-purity specialty solvents and chemicals for the pharmaceutical, food, environmental, and chemical testing sectors.

"BHC Perspective"

At Bengaluru Health Community, the Advanta bioKEMIX-Resolkem joint venture is a pharmaceutical supply chain self-reliance story of exactly the type that India's quality manufacturing agenda requires. The pharma sector cannot achieve GMP compliance without GMP-quality analytical reagents. Until now, India depended on imports for one of the most basic analytical prerequisites. Resolkem Private Limited is the domestic solution. For BHC founders in pharmaceutical analytical services, laboratory consumables, or pharma quality management technology — this is the kind of critical-input indigenisation that the industry has needed for years.

Frequently Asked Questions

Q: What is Resolkem Private Limited?
A: A new joint venture between Advanta bioKEMIX (Indian subsidiary of the bioKEMIX global network) and Anand Malage (Founder of Resolkem, ex-Cipla) — established as India's first dedicated manufacturer of GCHS-grade pharmaceutical solvents: DMF, DMA, NMP, and DMSO.

Q: What are GCHS-grade solvents used for?
A: Gas Chromatography-Headspace analysis — the regulatory-mandated technique for detecting and quantifying residual solvents in drug substances and drug products under ICH Q3C guidelines. High-purity GCHS-grade solvents are the prerequisite for compliant residual solvent testing across the entire pharmaceutical manufacturing sector.

Q: Why does domestic GCHS-grade solvent manufacturing matter?
A: It reduces India pharma's dependence on imported specialty analytical chemicals — lowering costs, reducing supply chain risk (as demonstrated by Operation Epic Fury logistics disruptions), and simplifying compliance documentation. Particularly important given India's increased GMP quality standards under revised Schedule M.